While various cardioprotective therapies exist, the risk of developing heart failure remains significantly higher in the T2DM population compared to non-diabetic individuals [4]. Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) represent a novel class of medications used for T2DM management due to their blood sugar-lowering effects. Here, SLC5A2 is linked to heart failure.